ArticleInternational journal of molecular epidemiology and genetics2014
Practical detection of a definitive biomarker panel for Alzheimer's disease; comparisons between matched plasma and cerebrospinal fluid.
Article in International journal of molecular epidemiology and genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Medical Histories of Control Subjects Influence the Biomarker Potential of Plasma Aβ in Alzheimer's Disease: a Meta-analysis.Journal of molecular neuroscience : MN · 2020Pooled it
- Association between clusterin concentration and dementia: a systematic review and meta-analysis.Metabolic brain disease · 2019Pooled it
- Plasma Proteomic Networks Reveal Shared Biology with Brain Linked to Alzheimer's Disease Pathology.medRxiv : the preprint server for health sciences · 2026Article
- Structural signature of plasma proteins classifies the status of Alzheimer's disease.Nature aging · 2026Article
- Whole exome sequencing analysis of suicidal thoughts and behaviors in a veteran cohort implicates inflammatory pathways and genes previously associated with psychiatric and neurodegenerative diseases.Journal of affective disorders · 2026Article
- Single-nucleus and spatial transcriptomic profiling of human temporal cortex and white matter reveals key associations with AD pathology.Nature communications · 2025Article
- Brain and plasmatic CLUSTERIN are translational markers of Alzheimer's disease.Brain pathology (Zurich, Switzerland) · 2025Article
- The neuroinflammatory role of microglia in Alzheimer's disease and their associated therapeutic targets.CNS neuroscience & therapeutics · 2024Review
- The emerging role of brain neuroinflammatory responses in Alzheimer's disease.Frontiers in aging neuroscience · 2024Review
- Fecal Proteome Profile in Dogs Suffering from Different Hepatobiliary Disorders and Comparison with Controls.Animals : an open access journal from MDPI · 2023Article
- Plasma and cerebrospinal fluid proteomic signatures of acutely sleep-deprived humans: an exploratory study.Sleep advances : a journal of the Sleep Research Society · 2023Article
- Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer's disease pathogenesis.Cellular and molecular life sciences : CMLS · 2019Review
- Glial activation and inflammation along the Alzheimer's disease continuum.Journal of neuroinflammation · 2019Article
- Postsynaptic Proteome of Non-Demented Individuals with Alzheimer's Disease Neuropathology.Journal of Alzheimer's disease : JAD · 2018Article
- SPARCL1 Accelerates Symptom Onset in Alzheimer's Disease and Influences Brain Structure and Function During Aging.Journal of Alzheimer's disease : JAD · 2018Article
- Role of Matricellular Proteins in Disorders of the Central Nervous System.Neurochemical research · 2017Review
- Rationalising the role of Keratin 9 as a biomarker for Alzheimer's disease.Scientific reports · 2016Article
- The dual roles of cytokines in Alzheimer's disease: update on interleukins, TNF-α, TGF-β and IFN-γ.Translational neurodegeneration · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
Abstract
Previous mass spectrometry analysis of cerebrospinal fluid (CSF) has allowed the identification of a panel of molecular markers that are associated with Alzheimer's disease (AD). The panel comprises Amyloid beta, Apolipoprotein E, Fibrinogen alpha chain precursor, Keratin type I cytoskeletal 9, Serum albumin precursor, SPARC-like 1 protein and Tetranectin. Here we report the development and implementation of immunoassays to measure the abundance and diagnostic capacity of these putative biomarkers in matched lumbar CSF and blood plasma samples taken in life from individuals confirmed at post-mortem as suffering from AD (n = 10) and from screened 'cognitively healthy' subjects (n = 18). The inflammatory components of Alzheimer's disease were also investigated. Employment of supervised learning techniques permitted examination of the interrelated expression patterns of the putative biomarkers and identified inflammatory components, resulting in biomarker panels with a diagnostic accuracy of 87.5% and 86.7% for the plasma and CSF datasets respectively. This is extremely important as it offers an ideal high-throughput and relatively inexpensive population screening approach. It appears possible to determine the presence or absence of AD based on our biomarker panel and it seems likely that a cheap and rapid blood test for AD is feasible.
Indexed as
Identifiers
24959311PMC4065395W1566803361What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.